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Abstract Vesicular monoamine transporter 2 (VMAT2)
is expressed in pancreatic beta cells and has recently been
proposed as a target for measurement of beta cell mass
in vivo. We questioned, (1) What proportion of beta cells
express VMAT2? (2) Is VMAT2 expressed by other pan-
creatic endocrine or non-endocrine cells? (3) Is the
relationship between VMAT2 and insulin expression dis-
turbed in type 1 (T1DM) or type 2 diabetes (T2DM)?
Human pancreas (7 non-diabetics, 5 T2DM, 10 T1DM)
was immunostained for insulin, VMAT2 and other pan-
creatic hormones. Most beta cells expressed VMAT2.
VMAT2 expression was not changed by the presence of
diabetes. In tail of pancreas VMAT2 immunostaining
closely correlated with insulin staining. However, VMAT2
was also expressed in some pancreatic polypeptide (PP)
cells. Although VMAT2 was not excluded as a target for
beta cell mass measurement, expression of VMAT2 in PP
cells predicts residual VMAT2 expression in human pan-
creas even in the absence of beta cells.
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Abbreviations
T1DM Type 1 diabetes
T2DM Type 2 diabetes
DTBZ Dihydrotetrabenazine
PET Positron emission tomography
VMAT2 Vesicular monoamine transporter 2
PP Pancreatic polypeptide
IRB Institutional review board
Introduction
Since both type 1 and type 2 diabetes are characterized by a
deficit of beta cell mass (Butler et al. 2007, 2003; Meier
et al. 2005; Ritzel et al. 2006), measurement of beta cell
mass in vivo is of interest. In order to evaluate beta cell
mass in vivo, a marker that can be detected by an imaging
approach that is targeted to beta cells is required. One
approach that has recently been applied to evaluate beta
cell mass in rats in vivo makes use of uptake of the radi-
oligand [11C]dihydrotetrabenazine (DTBZ) by the
membrane protein vesicular monoamine transporter 2
(VMAT2), and its subsequent detection by positron emis-
sion tomography (PET) (Simpson et al. 2006; Souza et al.
2006). VMAT2 is expressed in the central and peripheral
nervous system, the hematopoietic system and the neuro-
endocrine system (Anlauf et al. 2003, 2006; Eiden 2000;
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Erickson et al. 1996; Weihe and Eiden 2000; Weihe et al.
1994). VMAT2 mediates the uptake of monoamines from
the cytoplasm into secretory granules in monoamine-han-
dling cells (Eiden 2000; Erickson et al. 1996; Weihe and
Eiden 2000). [11C]DTBZ is already in clinical use for PET
imaging of brain in neurodegenerative disorders such as
Parkinson disease (Frey et al. 2001).
In the neuroendocrine system, VMAT2 is expressed in
chromaffin cells of the adrenal medulla, histamine-storing
enterochromaffin-like cells of the stomach, and pancreatic
islet cells (Anlauf et al. 2003; Erickson et al. 1996; Maffei
et al. 2004; Simpson et al. 2006; Weihe et al. 1994).
VMAT2 mRNA is more abundant in isolated islets than
exocrine pancreas in humans (Maffei et al. 2004). Immu-
nohistochemical studies in rodents and humans revealed
that VMAT2 is expressed in beta cells (Anlauf et al. 2003;
Simpson et al. 2006).
Based on these findings uptake of the radioligand
[11C]DTBZ in pancreas detected by PET was evaluated as
a method to measure beta cell mass in rats. Pancreatic
[11C]DTBZ uptake was decreased in rats with streptozo-
tocin (STZ)-induced diabetes and spontaneous type 1
diabetes (the BB-DP rat) compared to non-diabetic controls
(Simpson et al. 2006; Souza et al. 2006).
Recent studies in humans with long standing type 1
diabetes also revealed decreased pancreatic [11C]DTBZ
uptake compared to non-diabetic controls. However, sig-
nificant [11C]DTBZ uptake was observed in the pancreas of
patients with long standing type 1 diabetes (Freeby et al.
2007). This latter observation poses the question, are there
other cell types in the pancreas other than beta cells that
express VMAT2? Moreover is the pattern of VMAT2
expression disturbed in the setting of diabetes? We there-
fore studied human pancreas from non-diabetic controls,
recent onset and long established type 1 diabetes and
established type 2 diabetes to address the following ques-
tions. First, what proportion of pancreatic beta cells express
VMAT2? Second, is VMAT2 expressed by other endocrine
or non-endocrine cells in humans pancreas, and if so to what
extent? Third, is the relationship between VMAT2 and
insulin expression disturbed in type 1 or type 2 diabetes?
Methods
Study design
We first identified an antibody for VMAT2 with high
specificity and sensitivity in humans, and established the
optimal protocol for use of this antibody in human pancreas
tissue. We then applied this antibody simultaneously with
antibodies against either insulin, glucagon, somatostatin or
pancreatic polypeptide in human pancreas to establish the
specificity of VMAT2 expression to beta cells, the pro-
portion of beta cells that express VMAT2 and to what
extent these relationships are disturbed in diabetes.
Subjects and pancreatic tissue
Pancreas was obtained at autopsy at the Mayo Clinic from
21 cases and from surgery at UCLA from one case as
outlined in Table 1. Autopsy cases included 7 non-dia-
betics, 5 with type 2 diabetes (T2DM), 6 with long standing
type 1 diabetes (T1DM) and 3 with recent onset T1DM
who died of diabetic ketoacidosis (see Table 1). Pancreas
from one recent onset T1DM case was surgically removed
(Case 13). Pancreas in the cases of long standing and recent
onset T1DM cases were evaluated and included in prior
reports examining beta cell turnover in T1DM (Butler et al.
2007; Meier et al. 2005, 2006). IRB approval was obtained
from UCLA (surgical case) and Mayo Clinic (autopsy
cases). Written informed consent was provided by the
patient in whom the surgical sample was examined.
Potential autopsy cases were identified by retrospective
analysis of the Mayo Clinic autopsy database. To be
included, cases were required to (1) have had a full autopsy
within 12 h of death; (2) have had a general medical
examination, including at least one fasting blood glucose
documented within the year before death (the exception
being those with recent onset T1DM, who died at the first
admission shortly after diagnosis); and (3) pancreatic tissue
stored that was of adequate size and quality. Cases were
excluded if (1) potential secondary causes of diabetes were
present, (2) subjects had been exposed to chronic gluco-
corticoid treatment, or (3) pancreatic tissue had undergone
autolysis or showed evidence of pancreatitis.
Tissue preparation and immunohistochemistry
At autopsy, pancreas was resected from the tail and, with a
sample of spleen, fixed in formaldehyde and embedded in
paraffin for subsequent analysis (with two samples of head
of pancreas as per Table 1). The surgical specimen was a
distal pancreatectomy, as previously described (Butler
et al. 2007; Meier et al. 2006). Primary antibodies used in
this study are listed in Table 2. Sections (4 or 5 lm) were
cut from these paraffin blocks and stained by immunoflu-
orescence for insulin and VMAT2, using methods
previously described (Meier et al. 2005, 2006). All primary
antibodies with the exception of the anti-insulin antibody
were incubated with the slides overnight at 4C. The anti-
insulin antibody was incubated for 2 h at room
temperature.
Secondary antibodies conjugated to fluorescein isothio-
cyanate, Cy3, or Cy5 were diluted to 1:100 (Jackson
ImmunoResearch, West Grove, PA). All slides were cover
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slipped with Vectashield-DAPI mounting medium (Vector
Laboratories), stored in the dark at 4C, and analyzed
within 1–3 days after staining.
To assure specificity of antibody detection of VMAT2,
both a rabbit polyclonal anti-VMAT2 (Millipore) and a
goat polyclonal anti-VMAT2 (AbD Serotec) were used
Table 1 Characteristics of subjects
Number Sex Age (yrs) BMI (kg/m2) Duration of diabetes (yrs) FPG (mg/dl) Cause of death
Non-diabetics
1 M 40 17.6 – 89 Pneumonia
2 F 20 20.2 – 97 Congenital heart anomalies
3 F 46 25.8 – 99 Acute hepatic insufficiency
4 M 37 21.8 – 98 T cell lymphoma
5 F 46 15.4 – 83 Breast cancer, pneumonia
6a M 53 24.2 – NA Gastric cancer
7a F 21 19.9 – NA Empyema
T2DM
8 F 49 46.9 5 119 Acute pulmonary embolism
9 M 65 34.6 Unknown 188 Sepsis
10 F 62 44.7 7 121 Pneumonia
11 M 63 33.4 5 161 Bacterial pericarditis
12 F 78 30.7 15 116 Congestive heart failure
Recent onset T1DM
13b M 89 18.0 3 months 349 –
14 F 14 13.8 2 weeks 530 Diabetic ketoacidosis
15 F 36 25.9 Days 10 (4 days prior to death) Diabetic ketoacidosis
16 F 22 20.9 1 week 504 Diabetic ketoacidosis
Long standing T1DM
17 M 35 18.7 23 220 Pneumonia
18 F 38 21.1 25 253 Cerebral hemorrhage
19 F 40 34.7 23 462 Retroperitoneal hemorrhage
20 F 49 19.3 32 187 Acute myocardial infarction
21 F 51 17.4 39 273 Acute adrenal insufficiency
22 F 54 18.1 45 243 Pulmonary embolism
a Pancreas head, all other cases are tail
b Surgically removed tissue
FPG, fasting plasma glucose
NA, not available
Table 2 List of primary antibodies
Antigen Code Company Dilution Species
VMAT2 AB1767 Millipore, Temecula, CA 1:200 Rabbit, polyclonal
VMAT2 AHP1123 AbD Serotec, Oxford, UK 1:200 Goat, polyclonal
Insulin 18-0067 Invitrogen, Carlsbad, CA 1:100 Guinea pig, polyclonal
Glucagon G2654 Sigma, St. Louis, MO 1:1,000 Mouse, monoclonal
Somatostatin MAB354 Millipore 1:50 Rat, monoclonal
Pancreatic polypeptide NB100-1793 Novus Biologicals, Littleton, CO 1:150 Goat, polyclonal
Pancreatic polypeptide 18-0043 Invitrogen 1:100 Rabbit, polyclonal
Neuronal nuclei (NeuN) MAB377 Millipore 1:100 Mouse, monoclonal
Neuron-specific class III b-tubulin (TuJ-1) MO15013 Neuromics, Edina, MN 1:100 Mouse, monoclonal
Tyrosine hydroxylase MAB318 Millipore 1:100 Mouse, monoclonal
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(Table 2), side by side, in the immunofluorescence proto-
col. The same pattern of VMAT2 staining was observed
with both primary antibodies in human pancreatic tissue
(Supplementary Fig. 1a, b). We subsequently used the
rabbit polyclonal anti-VMAT2 antibody in this study. In
addition, to confirm the specificity of VMAT2 staining, the
rabbit polyclonal anti-VMAT2 antibody was preincubated
for 2 h with 10 or 100 excess of VMAT2 blocking peptide
(AG263, Millipore) or diluted with PBS. Blockage of
antibody was confirmed by immunohistochemistry in
adjacent sections of human pancreas (Supplementary
Fig. 1a, c, d).
Morphometric analysis
Fluorescent slides were viewed using a Leica DM6000
microscope (Leica Microsystems, Wetzlar, Germany) and
images were acquired using Openlab software (Improvi-
sion, Waltham, MA).
To measure the pancreatic fractional beta cell and
VMAT2 area, a montage of the whole pancreatic section
imaged at 950 magnification (95 objective) was created
using Openlab (Improvision) and ImageJ (National Insti-
tutes of Health, Bethesda, MD) software on a Leica
DM6000. The ratio of the beta cell area or VMAT2 area to
pancreas area was digitally quantified using Image Pro Plus
software (Media Cybernetics, Silver Springs, MD, USA) as
previously described (Meier et al. 2005, 2006).
The islets in each case were also analyzed at a higher
magnification (209 objective). At least 20 islets (with a
minimum of 4 beta cells per islet in plane of section) were
selected at random in each case. Scattered beta cells were
defined as a cluster of less than 4 beta cells in the same
section.
Confocal microscopy
The co-localization of VMAT2 and insulin or pancreatic
polypeptide was confirmed by use of a Leica spinning-disc
laser confocal microscope (DMIRE2; Leica) and images
were acquired using Velocity software (Improvision). The
series (z) sections were acquired with a 0.5 lm step size.
Fig. 1 Insulin and VMAT2
staining in a representative
pancreas from a non-diabetic
subject (a and b) and subject
with long standing type 1
diabetes (c and d). Insulin,
green; VMAT2, red; DAPI
(nucleus), blue. Insulin and
VMAT2 was abundantly present
in the pancreas of non-diabetic
control, but much less abundant
in the subject with long standing
type 1 diabetes. Original
magnification: 59. Scale
bars = 1 mm
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Statistical analysis
Data are presented as mean ± SEM. Statistical comparison
was carried out using the Student’s t test or one-way
ANOVA followed by Bonferroni’s post hoc correction. A
simple regression analysis was used to test the correlation
between beta cell area and VMAT2 area. A P value \ 0.05
was considered statistically significant.
Results
VMAT2 expression in non-diabetic human pancreas
VMAT2 expression was abundant in pancreas of non-dia-
betic subjects and its distribution overlapped substantially
with insulin expression (Figs. 1a, b, 2a–c). Co-localization
of insulin and VMAT2 expression was confirmed by con-
focal microscopy (Fig. 3). Most (88 ± 4%) beta cells
(defined as insulin staining) were also positive for VMAT2.
However, VMAT2 negative beta cells were invariably
present in each case.
The proportion of beta cells scattered in exocrine tissue
remote from islets that were positive for VMAT2 was
lower than beta cells within islets (29 ± 15% vs. 88 ± 4%
of beta cells, P \ 0.05). Insulin positive cells with exocrine
ducts were also less frequently positive for VMAT2 than
beta cells in islets (39 ± 7% vs. 88 ± 4%, P \ 0.05).
VMAT2 positive-insulin negative cells were also occa-
sionally seen within many islets (1.7 ± 0.3 cells per islet
cross section, Fig. 3). To further evaluate the nature of
these cells, we examined islets for VMAT2 double staining
vs. glucagon, somatostatin and pancreatic polypeptide
(PP). There was no co-localization of glucagon and
Fig. 2 Immuno-fluorescent
staining of representative islets
from a non-diabetic subject for
insulin (a, green), VMAT2 (b,
red) and insulin, VMAT2 and
nucleus using DAPI (blue)
merged (c). Most, but not all,
insulin staining cells are also
VMAT2 positive (yellow to
orange cells in c). VMAT2
staining was mostly confined to
the islet. For comparison
immuno-fluorescence with same
colors merged is shown in type
2 diabetes (d), recent onset type
1 diabetes (r-T1D, e) and long
standing type 1 diabetes (l-T1D,
f). A similar pattern of the
VMAT2 staining was seen in
the subjects with diabetes with
most, but not all, beta cells
positive for VMAT2 and
minimal VMAT2 staining
outside the islet. (f) Few beta
cells were seen in the islet
(indicated by arrows) of long
standing type 1 diabetic
subjects. VMAT2 positive beta
cells are indicated by arrow
heads. Original magnification:
209. Scale bars = 30 lm
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VMAT2 (Fig. 4a–c). Most of somatostatin positive cells
were also negative for VMAT2 (Fig. 4d–f), but a few
somatostatin positive cells (0–4% of the cells) were posi-
tive for VMAT2 (data not shown).
However, 39 ± 7% of islet PP positive cells also
expressed VMAT2 (Figs. 4g–i, 5). Co-localization of PP
and VMAT2 was confirmed by confocal microscopy
(Fig. 5a–c). VMAT2 positive PP cells were more frequent
in scattered groups of PP cells in the exocrine pancreas
compared to the PP cells within islets. As expected PP cells
were most abundant in the head of the pancreas where
VMAT2 positive PP cells were therefore also most fre-
quent (*70% of PP cells) (Fig. 4g–i). Triple staining for
PP, insulin and VMAT2 revealed that most of the VMAT2
positive-insulin negative cells could be accounted for as PP
cells (Fig. 5d–g). Only *1% of VMAT2 positive cells
were negative for both insulin and PP (Fig. 5g), and were
most likely mast cells or possibly nerve cells (Fig. 6). We
detected no co-localization of PP and insulin (Fig. 5).
VMAT2 expression in T2DM, T1DM recent
and long standing
The overall pattern of pancreatic VMAT2 expression was
comparable in type 1 and 2 diabetic subjects (Fig. 2d–f).
VMAT2 expression was, for the most part, co-localized
with insulin positive cells to the extent these were present.
As in non-diabetic subjects, most, but not all, beta cells
were also positive for VMAT2 (81 ± 4% and 72 ± 12%
of beta cells in subjects with T2DM and T1DM,
Fig. 3 Confocal image of a representative islet. Insulin, green;
VMAT2, red. Confocal microscopy confirmed the co-localization of
VMAT2 and insulin (a–c). It is noted that insulin positive but
VMAT2 negative cells (indicated by asterisk) and VMAT2 positive
but insulin negative cells (indicated by arrow heads) were seen within
the islets. Original magnification: 209. Scale bars = 30 lm. Images
are from a recent onset T1DM case
Fig. 4 Double staining of
VMAT2 and glucagon (a–c),
somatostatin (d–f) or pancreatic
polypeptide (PP) (g–i).
Glucagon, somatostatin or PP,
green; VMAT2, red; DAPI
(nucleus), blue. VMAT2
expression was co-localized
with neither glucagon (a–c) nor
somatostatin (d–f). However,
VMAT2 positive PP cells were
abundantly seen in pancreas
head ‘‘PP rich’’ lobe (g–i).
Original magnification: 209.
Scale bars = 50 lm. a–f,
images are from a recent onset
T1DM case; g–i, non-diabetic
case
548 J Mol Hist (2008) 39:543–551
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respectively). As in non-diabetic subjects, beta cells scat-
tered in exocrine tissue were less often VMAT2 positive
than beta cells in islets (37 ± 5% vs. 81 ± 4%, P \ 0.01
in T2DM, 30 ± 18% vs. 72 ± 12%, P = 0.1 in subjects
with T1DM (n = 4)).
Relationship between VMAT2 and insulin pancreatic
fractional area in all groups
Consistent with co-localization of insulin and VMAT2, the
fractional pancreatic (tail) insulin and VMAT2 positive
Fig. 5 (a–c) Confocal image of
a representative islet. PP, green;
VMAT2, red. Confocal
microscopy confirmed the co-
localization of VMAT2 and PP
(a–c, indicated by arrowheads).
In tail of the pancreas * 40%
of PP cells were positive for
VMAT2. d–g) Triple staining
for PP (green, d), insulin (blue,
e), VMAT2 (red, f) and merged
image (g). VMAT2 positive
beta cells are seen as purple
cells in g. Triple staining
revealed that the VMAT2
positive but insulin negative
cells were PP cells (g, yellow
cells indicated by arrows),
although VMAT2 positive but
both insulin and PP negative
cells were still seen occasionally
(g, indicated by arrowhead),
which are likely mast cells or
neuron cells. Original
magnification: 209. Scale
bars = 15 (a–c) or 30 lm (d–
g). Images are from a recent
onset T1DM case
Fig. 6 (a) Bundle of VMAT2 positive nerve fibers surrounded by
connective tissue in the pancreas. VMAT2, red; DAPI (nucleus), blue.
(b) VMAT2 positive nerve fibers (arrowhead), but not VMAT2
positive cells (asterisks) were co-stained with neuron marker (green).
Neuron marker (NeuN and Tuj-1), green; VMAT2, red; DAPI
(nucleus), blue. Original magnification: 209. Scale bars = 30 lm.
Images are from a recent onset T1DM case
J Mol Hist (2008) 39:543–551 549
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area were comparably decreased in the subjects with dia-
betes (Figs. 1c, d, 7). The fractional (tail) pancreatic
VMAT2 positive area was slightly greater than the corre-
sponding beta cell fractional area when all cases (non-
diabetic, T1DM, T2DM) were included (0.71 ± 0.17% vs.
0.63 ± 0.17%, P \ 0.01), the excess VMAT2 fractional
area (VMAT2 fractional area—beta cell fractional area)
was comparable in each group (0.08 ± 0.06%,
0.08 ± 0.03%, 0.06 ± 0.11% and 0.09 ± 0.03% in non-
diabetics, T2DM, recent onset T1DM and long standing
T1DM, respectively, P = 0.9). As a result, in the tail of the
pancreas the pancreatic VMAT2 fractional area was
strongly correlated with pancreatic beta cell fractional area
(r2 = 0.98) described by the equation;
VMAT2 positive area %ð Þ ¼ beta cell area %ð Þ þ 0:1:
Discussion
Our overall objective in this study was to establish the
relationship between VMAT2 and insulin expression in
human pancreas, and in particular to establish if this rela-
tionship is disturbed in either type 1 or type 2 diabetes.
We report that there is excellent overlap between
VMAT2 and insulin expression in the tail of the human
pancreas, and that this relationship is not altered in either
patients with type 1 or type 2 diabetes. However,we also
report that approximately 40% of PP cells also express
VMAT2. PP cells are most abundant in the head of the
pancreas, a region of pancreas that we did not have access
to in most cases. However, uptake of the radio-ligand
[11C]DTBZ by via VMAT2 in human pancreas presum-
ably reflects the whole pancreas, including the PP enriched
head of pancreas. From our data one would predict that
there would be residual [11C]DTBZ uptake in pancreas of
patients with even long standing T1DM with minimal beta
cell mass. This is indeed the finding in clinical studies
(Freeby et al. 2007; Liu et al. 2007). With this insight it
will be of interest to seek to establish methods that might
permit measurement of VMAT2 uptake selectively in the
tail of the pancreas.
In one prior study of human pancreas VMAT2 and PP
were not reported to be co-localized (Anlauf et al. 2003).
The reason for the difference between that study and our
present report is not clear, but perhaps may relate to the
relatively low frequency of PP cells in the tail and body of
the pancreas. The co-localization of VMAT2 to a propor-
tion of PP cells became most obvious in the head of the
pancreas where PP cells are most abundant. To confirm this
finding we reproduced the co-localization of VMAT2 and
PP using different primary antibodies for both proteins
(Table 2). Moreover, in the prior human study 5 of 8 non-
functioning well-differentiated pancreatic endocrine
tumors with PP immunophenotype (among them only one
tumor coincided with insulin immunophenotype) were
VMAT2 positive (Anlauf et al. 2003).
A previously unnoted finding reported here is that
approximately 10% of pancreatic beta cells in islets are
VMAT2 negative while this proportion increases to *70%
in beta cells scattered in the exocrine tissue remote from
pancreatic islets, a pattern that was comparable in both
non-diabetic cases and those with T1DM and T2DM. It is
unknown whether beta cells that express VMAT2 are
functionally distinct from those that do not, or what the
basis of this difference is. While the function of VMAT2
expression by beta cells is unknown, monoamines taken up
by VMAT2 such as histamine, norepinephrine, dopamine
and serotonin have been reported to modulate beta cell
function (Ahren 2000; Brunicardi et al. 1995).
One possible explanation for our detection of VMAT2
staining in some but not all beta cells is that the subcellular
localization of VMAT2 is polar in which case beta cells may
appear negative for VMAT2 if the cellular pole enriched in
VMAT2 expression is out of the plane of section. To address
this possibility we used confocal imaging which affirmed
that there are two distinct populations of pancreatic beta
cells that either do or do not express VMAT2. Moreover
VMAT2 positive and VMAT2 negative monoaminergic
neuron cells have been reported in the central nervous sys-
tem (Eiden 2000; Weihe and Eiden 2000). While Anlauf
et al. reported that all beta cells expressed VMAT2 in non-
neoplastic human pancreas, in the same study VMAT2
positive cells were detected in only 10 of 34 benign insuli-
nomas and 5 of 10 malignant insulinomas (Anlauf et al.
2003), consistent with the heterogeneity of VMAT2
expression in beta cells observed here.
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Fig. 7 Correlation between fractional pancreas beta cell vs. VMAT2
positive area in tail of pancreas. There was a close correlation
between fractional beta cell and VMAT2 positive area. However, the
regression line does not run through the zero-point (y = x ? 0.1).
Square, non-diabetics; circle, type 2 diabetes; reverse triangle, recent
onset type 1 diabetes; triangle, long standing type 1 diabetes
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In conclusion, we report a close linear correlation
between insulin and VMAT2 immunostaining in the tail of
pancreas in humans with and without diabetes. Although
this result supports the concept of non-invasive measure-
ment of beta cell mass in humans by using [11C]DTBZ and
PET, caution will be needed to interpret the results because
of VMAT2 expression in PP cells as well as heterogenous
VMAT2 expression among beta cells.
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